SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week interval between doses.

Abstract

Continuous emergence of SARS-CoV-2 variants of concern (VOCs) is fueling the COVID-19 pandemic. Omicron (B.1.1.529) rapidly spread worldwide. The large number of mutations in its Spike raise concerns about a major antigenic drift that could significantly decrease vaccine efficacy and infection-induced immunity. A long interval between BNT162b2 mRNA doses elicits antibodies that efficiently recognize Spikes from different VOCs. Here, we evaluate the recognition of Omicron Spike by plasma from a cohort of SARS-CoV-2 naive and previously infected individuals who received their BNT162b2 mRNA vaccine 16 weeks apart. Omicron Spike is recognized less efficiently than D614G, Alpha, Beta, Gamma, and Delta Spikes. We compare with plasma activity from participants receiving a short (4 weeks) interval regimen. Plasma from individuals of the long-interval cohort recognize and neutralize better the Omicron Spike compared with those who received a short interval. Whether this difference confers any clinical benefit against Omicron remains unknown.

• Authors: Debashree Chatterjee, Alexandra Tauzin, Lorie Marchitto, Shang Yu Gong, Marianne Boutin, Catherine Bourassa, Guillaume Beaudoin-Bussières, Yuxia Bo, Shilei Ding, Annemarie Laumaea, Dani Vézina, Josée Perreault, Laurie Gokool, Chantal Morrisseau, Pascale Arlotto, Éric Fournier, Aurélie Guilbault, Benjamin Delisle, Inès Levade, Guillaume Goyette, Gabrielle Gendron-Lepage, Halima Medjahed, Gaston De Serres, Cécile Tremblay, Valérie Martel-Laferrière, Daniel E Kaufmann, Renée Bazin, Jérémie Prévost, Sandrine Moreira, Jonathan Richard, Marceline Côté, Andrés Finzi
• Journal: Cell reports (Cell Rep) Vol. 38 Issue 9 Pg. 110429 (03 01 2022) ISSN: 2211-1247 [Electronic] United States
• PMID: 35216664 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.

Chemical References

• Antibodies, Neutralizing
• Antibodies, Viral
• Spike Glycoprotein, Coronavirus
• Vaccines, Synthetic
• mRNA Vaccine
• mRNA Vaccines
• spike protein, SARS-CoV-2
• BNT162 Vaccine

Topics

• Adult
• Aged
• Antibodies, Neutralizing (analysis, blood, immunology)
• Antibodies, Viral (analysis, blood, immunology)
• BNT162 Vaccine (administration & dosage, immunology)
• Cohort Studies
• Female
• HEK293 Cells
• Humans
• Immunization Schedule
• Immunization, Secondary (methods)
• Male
• Middle Aged
• Quebec
• SARS-CoV-2 (immunology, pathogenicity)
• Spike Glycoprotein, Coronavirus (immunology)
• Time Factors
• Vaccination (methods)
• Vaccine Potency
• Vaccines, Synthetic (administration & dosage, immunology)
• Young Adult
• mRNA Vaccines (administration & dosage, immunology)